THE WOODLANDS, Texas--(BUSINESS WIRE)--MolecularHealth announced today that Medical Director Gabriel Bien-Willner, M.D., Ph.D., will speak at this year’s Personalized Medicine Conference. Dr. Bien-Willner will join other industry experts on the panel “Novel Approaches to Personalized Medicine.” The conference will take place November 12-13, 2014 at Harvard Medical School in Boston, Mass. MolecularHealth will also be participating as a conference sponsor.
Approaches to treating cancer and other diseases have advanced as our knowledge of the role of genetics and genomics continues to grow. New technologies and a better understanding of what drives disease have led to the development of targeted therapies and more accurate tests. The panel “Novel Approaches to Personalized Medicine” will discuss medicine’s new perspective on disease and the emerging business models being built around a personalized medicine approach.
“The genomic revolution has provided us with an incredible amount of data on disease, what drives it and why it presents differently in every individual,” said Dr. Bien-Willner. “But, to deliver on the promise of personalized medicine, having the data is not enough. It’s the ability to translate these massive data sets into clinically actionable information that is essential to furthering our field and providing actual results to more patients. This is the challenge that businesses and organizations within our industry are currently facing and this panel will shed light on some real solutions.”
MolecularHealth uses computational approaches of interpretation to unlock the clinical value of large quantities of genomic data. Its TreatmentMAP™ solution provides a best-in-class software and diagnostic platform for molecular interpretation, drug safety and unique treatment decision support for oncologists and each of their cancer patients.
The 10th Annual Personalized Medicine Conference is co-hosted and presented by Partners Healthcare Personalized Medicine, Harvard Business School and Harvard Medical School in association with the American Association for Cancer Research and Personalized Medicine Coalition. The panel “Novel Approaches to Personalized Medicine” will take place on November 12, 2014 at 4:00 p.m. For more information on the 10th Annual Personalized Medicine Conference, please visit the event page.
MolecularHealth is a leading biomedical company that is transforming molecular data into clinically actionable information to inform the most efficient and safest cancer treatment options for each individual cancer patient.
In the U.S., TreatmentMAPTM is a laboratory developed test (LDT) performed at MolecularHealth’s CLIA-certified laboratory. In Europe, TreatmentMAP is the first registered medical device of its kind for personalized cancer medicine and offered through a network of certified physicians. MolecularHealth GmbH is certified according to DIN EN ISO 13485.
MolecularHealth, comprised of a multidisciplinary team of oncologists, scientists, businesspeople, and IT experts with long-standing expertise in their fields, works in partnership with some of the world’s leading healthcare, information technology and NGS companies, including the U.S. Food and Drug Administration (FDA), University of Texas MD Anderson Cancer Center, SAP AG and GATC Biotech.
Located in the centers of cancer research in Europe and U.S., the company is headquartered in Heidelberg, Germany, and its U.S. headquarters, including a CLIA-certified NGS lab, is located in The Woodlands, Texas. The company also has offices in Boston, Mass.